# ipsen.com

> AI-optimized mirror of ipsen.com containing 50 pages totalling 44,575 words of clean markdown content, structured data, and semantic HTML. Original source: https://ipsen.com. Last updated: 2026-09-07T02:41:18.417Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care](/content/site-root.html): Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world. (576 words)

## Articles & Blog Posts

- [Ipsen Media Library | Ipsen Global](/content/media-resources/index.html): Browse through Ipsen's media library, a comprehensive resource for healthcare information, research findings, and updates on our innovative solutions. (246 words)
- [Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor](/content/press-release/ipsen-and-day-one-enter-into-exclusive-ex-u-s-licensing-agreement-to-commercialize-tovorafenib-for-the-most-common-childhood-brain-tumor-2918482.html):   PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain (1,562 words)
- [Investors - Suscribe to Ipsen News - Global](/content/investors-suscribe-to-ipsen-news/index.html) (261 words)
- [ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio - Global](/content/update/esmo-2025-new-data-reinforces-breadth-and-depth-of-ipsens-growing-oncology-pipeline-and-portfolio-3165272.html): Eight Ipsen and partner abstracts demonstrate how bold science is leading to new standards of cancer care and meaningful progress for patients across tumor types Subgroup analysis from the landmark Phase III CABINET trial shows improved progression-free survival with Cabometyx® versus placebo in advanced lung and thymic neuroendocrine tumors1 Ipsen’s pioneering early science is reflected (1,637 words)
- [Work at Ipsen and discover the benefits | Ipsen Global](/content/careers/working-at-ipsen/index.html): Here at Ipsen, there are endless challenges and rewards. Opportunities across the globe. A team empowered by collaboration. (545 words)
- [Ipsen Investors | Investment Information & Updates](/content/investors/index.html): Access investment information and updates at Ipsen. Find our investor resources and stay informed about our financial performance, reports, and investor events. (418 words)
- [Ipsen responsibility: Governance](/content/aus/responsibility/governance/index.html): Explore Ipsen’s commitment to ethics and transparency, supported by our strong governance, responsible practices and anti-corruption initiatives. (2,068 words)
- [Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business](/content/press-release/ipsen-presents-strong-full-year-2021-results-and-enters-into-exclusive-negotiations-to-divest-its-consumer-healthcare-business.html): Strong 2021 financial performance with total-sales growth of 12.3% at CER1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%) Exclusive negotiations with Mayoly Spindler to divest Ipsen’s Consumer Healthcare (CHC) business with a total enterprise value up to €350m and an anticipated closing of the transaction by (1,494 words)
- [Shareholders Information at Ipsen | Valuable Insights for Shareholders](/content/investors/shareholders-information/index.html): Ipsen’s shareholders can find important information regarding shareholding, analyst coverage and the ADR program. We're committed to transparency and providing timely information to our shareholders. (389 words)
- [Explore Careers at Ipsen | Ipsen Global](/content/careers/index.html): Explore Ipsen careers in a variety of fields. Search Ipsen jobs according to your unique skills, and make a real impact on patients’ lives. (342 words)
- [Discover Ipsen Values : Way of Being | Ipsen Global](/content/careers/our-culture/index.html): Discover Ipsen's culture and values, and how they shape our commitment to innovation and improving patient outcomes in the biopharmaceutical industry. (242 words)
- [Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders](/content/press-release/ipsen-and-exicure-enter-into-exclusive-collaboration-targeting-rare-neurodegenerative-disorders-2.html): Ipsen obtains exclusive options to Spherical Nucleic Acids (SNAsTM) currently under discovery evaluation for Huntington’s disease and Angelman syndrome Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exercises its option to the two programs, Ipsen will be responsible for further development and worldwide commercialization Exicure will receive a (620 words)
- [Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio](/content/press-release/ipsen-to-acquire-memo-therapeutics-ag-adding-first-in-class-bk-polyomavirus-antibody-expanding-rare-disease-portfolio-3320317.html): Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year Ipsen expands rare disease portfolio to include serious and frequent post-transplant infection with no targeted approved treatments PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, (1,271 words)
- [Ipsen Media Updates | Official Announcements & Updates](/content/media-updates/index.html): Stay informed with Ipsen's official announcements and updates. Read our media updates for the latest news on our research, products, and initiatives. (75 words)
- [Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio](/content/press-release/ipsen-to-acquire-clementia-pharmaceuticals-to-significantly-boost-rare-disease-portfolio.html): Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisition to transform Ipsen’s Rare Disease portfolio by leveraging Clementia’s expertise and Ipsen’s global commercial footprint to provide life-altering treatments to patients with unmet medical needs Ipsen (1,904 words)
- [Investor Events at Ipsen | Engaging with Our Investor Community](/content/investors/investor-events/index.html): Learn about upcoming investor events at Ipsen. Join us as we engage with our investor community and share updates on our strategic initiatives. (119 words)
- [Governance at Ipsen | Upholding Ethical Business Practices](/content/sustainability/governance/index.html): Explore Ipsen’s commitment to ethics and transparency, supported by our strong governance, responsible practices and anti-corruption initiatives. (1,731 words)
- [Newsroom - Subscribe to Ipsen News - Global](/content/newsroom-subscribe-to-ipsen-news/index.html) (96 words)
- [Corporate social responsibility | Ipsen Global](/content/sustainability/index.html): Discover Ipsen's commitment to corporate responsibility and sustainability. (942 words)
- [Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery](/content/press-release/ipsen-to-acquire-exclusive-rights-to-investigational-erk-inhibitor-as-part-of-its-existing-research-collaboration-with-agv-discovery.html): PARIS, & MONTPELLIER, FRANCE, 1st August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and AGV Discovery today announced that Ipsen has exercised its option to acquire exclusive worldwide rights to an investigational ERK inhibitor, discovered by AGV Discovery. The decision follows the successful achievement of a key developmental milestone and is the result of a research (1,147 words)
- [Ipsen completes acquisition of Epizyme expanding its portfolio in oncology](/content/press-release/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology.html): PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates (1,143 words)
- [Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinic](/content/press-release/ipsen-and-marengo-therapeutics-announce-strategic-partnership-to-advance-two-precision-immuno-oncology-candidates-from-marengos-star-platform-into-the-clinic.html): PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 01 August, 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics, Inc. today announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint (1,303 words)
- [Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline](/content/press-release/ipsen-to-acquire-kartos-therapeutics-expanding-hemato-oncology-late-stage-pipeline-3318643.html): Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 inhibitor, has the potential, through disease modifying activity, to transform suboptimal responses to standard of care ruxolitinib into clinically meaningful responses in patients with myelofibrosis Top-line data from the (1,282 words)
- [Acquisition of Albireo has been completed | Ipsen Global](/content/press-release/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio.html): Ipsen has completed its acquisition of Albireo, expanding the scope of its rare disease portfolio. (1,320 words)
- [Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)](/content/press-release/ipsen-and-blueprint-medicines-announce-exclusive-global-license-agreement-to-develop-and-commercialize-blu-782-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-fop.html): — Expands Ipsen’s Rare Diseases portfolio to include BLU-782,a highly selective investigational ALK2 inhibitor for the treatment of FOP —— Accelerates global development of BLU-782 through Ipsen’s clinical expertisein rare diseases and global infrastructure —— Blueprint Medicines is eligible to receive up to $535 million, including a $25 million upfront payment and up to $510 million in (1,015 words)
- [Financial Results at Ipsen | Detailed Financial Performance](/content/investors/financial-results/index.html): Learn about Ipsen’s latest financial results; access historical financial data. Understand our financial performance over the years through comprehensive reports. (254 words)
- [Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance](/content/press-release/ipsen-delivers-excellent-h1-2026-results-and-upgrades-its-full-year-guidance-3335743.html): H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8%1 and core operating income of €845m, growing by 28.8% as reported, with a core operating margin of 38.6% of total sales, increasing by 2.5 points Upgraded FY 2026 financial guidance2: total (1,283 words)
- [Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease](/content/press-release/ipsen-and-irlab-enter-exclusive-worldwide-licensing-agreement-aimed-to-improve-the-lives-of-people-living-with-parkinsons-disease.html): Ipsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action Mesdopetam, an oral dopamine D3-receptor antagonist, has completed Phase Ib and IIa clinical programs which showed promising improvements for people living with Parkinson’s disease experiencing levodopa-induced dyskinesia (LID) in clinically relevant endpoints (1,033 words)
- [Compliance - United States](/content/us/compliance/index.html): Ipsen Statement regarding compliance with California Health and Safety Code § 119402 NOTICE: This information is provided pursuant to the requirements of California Health & Safety Code, Section 119402, which requires pharmaceutical companies doing business in California to make available their Compliance Program and also to provide annual written declaration of their adherence to the (727 words)
- [Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential](/content/press-release/ipsen-and-foreseen-biotechnology-announce-exclusive-global-licensing-agreement-for-antibody-drug-conjugate-with-first-in-class-potential-2911523.html): Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified through the application of Foreseen’s proprietary proteomic platforms FS001 has demonstrated robust preclinical efficacy in multiple tumor models and (788 words)
- [Exclusive Licensing Agreement with GENFIT | Ipsen Global](/content/press-release/ipsen-and-genfit-enter-into-exclusive-licensing-agreement-for-elafibranor-a-phase-iii-asset-evaluated-in-primary-biliary-cholangitis-as-part-of-a-long-term-global-partnership.html): Discover the exclusive licensing agreement between Ipsen and GENFIT as part of a long term global agreement. (686 words)
- [Cabozantinib Ipsen® (cabozantinib) accepted by Scottish Medicines Consortium for adults with advanced neuroendocrine tumours - UK Ireland](/content/uk-ireland/press-releases/cabozantinib-ipsen-cabozantinib-accepted-by-scottish-medicines-consortium-for-adults-with-advanced-neuroendocrine-tumours.html): LONDON, U.K., 10 August 2026 – Ipsen U.K. (Euronext: IPN; ADR: IPSEY) announced today that cabozantinib is accepted by the SMC for restricted use within NHS Scotland for the treatment of adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy (728 words)
- [Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors](/content/press-release/ipsen-and-sutro-biopharma-announce-exclusive-global-licensing-agreement-for-an-adc-targeting-solid-tumors.html): Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target STRO-003 has shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological malignancies1 PARIS, (708 words)
- [Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3](/content/press-release/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3.html): Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent Therapeutics reinforces Ipsen’s expansion into hematological malignancies, with a focus on acute myeloid leukemia Paris (France), 18 October 2021 – Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive (502 words)
- [Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity](/content/press-release/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity-3297909.html): Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport® (abobotulinumtoxinA) was non-inferior to Botox® (onabotulinumtoxinA) in adult patients with upper limb spasticity Patients treated with Dysport in the DIRECTION trial achieved a longer duration of response than patients treated (838 words)
- [Reports and Accounts at Ipsen | Comprehensive Financial Information](/content/investors/reports-and-accounts/index.html): Access comprehensive financial information through Ipsen's reports and accounts. Stay informed about our financial health and business performance. (168 words)
- [Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma](/content/press-release/arbitration-tribunal-upholds-ipsens-termination-of-rd-agreement-with-galderma-3223087.html): PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. The ICC Tribunal’s decision confirms Ipsen’s (404 words)
- [Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate](/content/press-release/ipsen-expands-early-development-pipeline-with-simcere-zaimings-innovative-antibody-drug-conjugate-3208932.html): Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy data Program expected to enter Phase I clinical development in H2 2026 Simcere Zaiming is eligible to receive up to $1.06B in total (660 words)
- [Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.](/content/press-release/dysport-is-the-first-botulinum-toxin-to-achieve-positive-topline-phase-iii-results-in-both-episodic-and-chronic-migraine-3324543.html): Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to demonstrate a statistically significant reduction in monthly migraine days Dysport was well-tolerated across both trials with safety consistent with the known profile PARIS, FRANCE – 9 (792 words)
- [Morgan Stanley Healthcare Conference - Global](/content/event/morgan-stanley-healthcare-conference/index.html) (109 words)
- [Ipsen updates on QM-1114 regulatory process](/content/press-release/ipsen-updates-on-qm-1114-regulatory-process/index.html): PARIS, FRANCE, 3 October 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its partner Galderma has confirmed receipt from the FDA of a Complete Response Letter related to its Biologics License Application for liquid botulinum toxin type A (QM-1114), noting certain deficiencies related to chemical, manufacturing and controls (CMC) processes. Furthermore, on 28 (526 words)
- [Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)](/content/press-release/ipsen-s-a-publishes-its-2026-half-year-report-half-year-ended-30-june-2026-3336267.html): Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026) Attachment 2026 Half-year Financial Report_Ipsen S.A. (58 words)
- [Ipsen Regulated Information | Investor Relations](/content/investors/regulated-information/index.html): Access Ipsen's regulated information for investors, including financial reports, press releases, and other important updates. (106 words)
- [Ipsen to Acquire Epizyme - Growth in Oncology | Ipsen Global](/content/press-release/ipsen-to-acquire-epizyme-expanding-its-portfolio-in-oncology.html): Ipsen has announced its acquisition of Epizyme, a move that will allow Ipsen to further establish itself as a leader in the field of oncology and provide new treatment options for cancer patients. (4,186 words)
- [2025 Integrated Annual Report - Global](/content/annual-report/2025-integrated-annual-report/index.html) (22 words)
- [Ipsen to Acquire Albireo - Growth in Rare Disease | Ipsen Global](/content/press-release/ipsen-to-acquire-albireo-accelerating-growth-in-rare-disease-with-treatments-for-several-pediatric-liver-diseases.html): The acquisition will allow Ipsen to expand its portfolio of rare disease treatments and further establish itself as a leader in the field. (5,249 words)
- [Our 2025 Sustainability Statement is Live: Here's What It Means for Ipsen - Global](/content/stories/sustainability/ipsens-2025-sustainability-statement-is-availab/index.html): Ipsen’s 2025 Sustainability Statement - the annual publication outlining Ipsen’s environmental, social and governance (ESG) commitments, progress and priorities - is now available (326 words, Apr 1, 2026)
- [5 Ways Ipsen Keeps Compliance at Our Core - United States](/content/us/midsize-big-vision/5-ways-ipsen-keeps-compliance-at-our-core/index.html): Jesse Siegel, Head of U.S. Business Ethics at Ipsen, reflects on 5 key components of our strong compliance culture and how we navigate an ever-evolving industry landscape. (657 words, Nov 4, 2024)

## Products

- [Dysport® (AbobotulinumtoxinA) - Germany](/content/germany/product/dysport-abobotulinumtoxina/index.html) (17 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives
- [AgentSite Network](https://agentsite.network/network.html): Public index of AgentSites and their machine-readable resources